MedTrace Logo

Mechanisms of Resistance to PSMA Radioligand Therapy

NCT05435495 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2026-03-18

No results posted yet for this study

Summary

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Conditions

Interventions

PROCEDURE

Single-photon emission computed tomography

Imaging procedure

PROCEDURE

Blood Draw

Blood draw for future research tests (45-60 mL).

PROCEDURE

Tumor Biopsy

Guided biopsy of lesion

Sponsors & Collaborators

Principal Investigators

  • Thomas Hope, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435495 on ClinicalTrials.gov